Evidence map›Paper›PMID 35890044›Full record

ReviewPathogens (Basel, Switzerland)2022

RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease.

Chandrasekharan Rajalekshmi Dhanya, Aswathy Shailaja, Aarcha Shanmugha Mary, Sumodan Padikkala Kandiyil, Ambili Savithri, Vishnu Sasidharan Lathakumari, Jayakrishnan Therthala Veettil, Jiji Joseph Vandanamthadathil, Maya Madhavan

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chandrasekharan Rajalekshmi DhanyaDepartment of Biochemistry, Government College Kariavattom, Thiruvananthapuram 695581, India.
Aswathy ShailajaDepartment of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-0173-7106
Aarcha Shanmugha MaryDepartment of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Thiruvarur 610105, India.ORCID 0000-0002-6747-6789
Sumodan Padikkala KandiyilPost Graduate Department of Zoology, Government College, Vadakara 673102, India.
Ambili SavithriDepartment of Biochemistry, Sree Narayana College, Kollam 691001, India.
Vishnu Sasidharan LathakumariDepartment of Biochemistry and Industrial Microbiology, Sree Narayana College for Women, Kollam 691001, India.
Jayakrishnan Therthala VeettilDepartment of Zoology, Government Brennen College, Thalassery 670106, India.
Jiji Joseph VandanamthadathilDepartment of Zoology, Government Brennen College, Thalassery 670106, India.
Maya MadhavanDepartment of Biochemistry, Government College for Women, Thiruvananthapuram 695014, India.ORCID 0000-0003-4991-6899

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic viruses with an RNA genome represent a challenge for global human health since they have the tremendous potential to develop into devastating pandemics/epidemics. The management of the recent COVID-19 pandemic was possible to a certain extent only because of the strong foundations laid by the research on previous viral outbreaks, especially Ebola Virus Disease (EVD). A clear understanding of the mechanisms of the host immune response generated upon viral infections is a prime requisite for the development of new therapeutic strategies. Hence, we present here a comparative study of alterations in immune response upon SARS-CoV-2 and Ebola virus infections that illustrate many common features. Vaccination and pregnancy are two important aspects that need to be studied from an immunological perspective. So, we summarize the outcomes and immune responses in vaccinated and pregnant individuals in the context of COVID-19 and EVD. Considering the significance of immunomodulatory approaches in combating both these diseases, we have also presented the state of the art of such therapeutics and prophylactics. Currently, several vaccines against these viruses have been approved or are under clinical trials in various parts of the world. Therefore, we also recapitulate the latest developments in these which would inspire researchers to look for possibilities of developing vaccines against many other RNA viruses. We hope that the similar aspects in COVID-19 and EVD open up new avenues for the development of pan-viral therapies.

Indexed as

COVID-19Ebolaimmune responselymphopeniapregnancyRNA virusSARS-CoV-2T-cell exhaustionvaccine

Identifiers

PMID35890044
PMCPMC9322689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.